Target
microtubules
Aliases
microtubule
18 products, 23 indications
Indications
metastatic non-small cell lung cancer (3 products)
platinum-resistant high-grade serous ovarian cancer (3 products)
Ovarian Cancer (3 products)
glioblastoma (2 products)
NSCLC (2 products)
advanced non-squamous NSCLC (2 products)
NRAS-mutant unresectable stage III or IV melanoma (2 products)
stage IV NSCLC (1 products)
non-small lung cancer (1 products)
NF1-mutant advanced melanoma (1 products)
EGFR-negative refractory advanced NSCLC (1 products)
HER2-negative locally advanced or metastatic breast cancer (1 products)
Relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma (1 products)
HR+/HER2- early-stage breast cancer (1 products)
Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Bladder Cancer, Ovarian Cancer, Triple Negative Breast Cancer, Cervical Cancer (1 products)
Stage III unresectable NSCLC with EGFR mutations (1 products)
Metastatic Castration-Resistant Prostate Cancer (1 products)
metastatic hormone-resistant prostate cancer (1 products)
Clear Cell Carcinoma (1 products)
Oligometastatic castration-resistant prostate cancer (1 products)
recurrent ovarian cancer (1 products)
recurrent advanced ovarian cancer (1 products)
recurrent low-grade serous ovarian cancer (1 products)
Loading...
5 drugs
263 abstracts
Abstract
Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study.Org: Hospital Universitario 12 de Octubre, Madrid, Spain, Hospital Universitari i Politécnic La Fe de Valencia, Valencia, Spain, Henry Dunant Hospital Center, Athens, Greece, Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain, Asklepios Lung Clinic, German Center for Lung Research (DZL), Munich-Gauting, Germany,
Abstract
Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).Org: University of Milan and European Institute of Oncology, IRCCS, Fudan University Shanghai Cancer Center, Division of Medical Oncology, National Cancer Centre of Singapore, National Cancer Center Hospital East, Kashiwa, Japan, Latin American Cooperative Oncology Group (LACOG),
Abstract
ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome.Org: Gustave Roussy Cancer Center, Biostatistics Unit, Hopital Cochin, Chi Creteil, Centre François Baclesse,
Abstract
ECOG-ACRIN EAZ171: Prospective validation trial of germline variants and taxane type in association with taxane-induced peripheral neuropathy (TIPN) in Black women with early-stage breast cancer.Org: Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Malden, MA,
Abstract
A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial.Org: Yonsei University College of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Gangnam Severance Hospital, Seoul St. Mary's Hospital,
Abstract
Updated results and biomarker analyses from the phase 2 trial of nab-paclitaxel plus sintilimab as second-line therapy for advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (G/GEJA).Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Science,Peking Union Medical College, Chinese Academy of Medical Sciences and Peking Union Medical College, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Chinese Academy of Medical Science and Peking Union Medical College,
Abstract
Neoadjuvant pegylated liposomal doxorubicin-containing chemotherapy in combination with trastuzumab and pertuzumab in patients with HER2-positive early breast cancer: A randomized phase II study (METIS).Org: Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, Cancer Center, Sun Yat-sen University, Guangzhou, China, Shantou Central Hospital, Shantou, China,
Abstract
KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.Org: Sichuan Cancer Hospital and Institute, Chengdu, China, Louis Pradel Hospital, Hospices Civils de Lyon Cancer Institute, Lyon, France; Cancer Research Center of Lyon (INSERM 1052, CNRS 5286), Lyon, France; Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France, Institut de Cancérologie de l'Ouest, Saint-Herblain, France, Hospital Universitario Son Espases, Mallorca, Spain, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy,
Abstract
A phase II trial comparing dalpiciclib in combination with letrozole versus standard chemotherapy as neoadjuvant therapy in patients with high-risk HR- positive HER-2 negative breast cancer: DARLING-02.Org: The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, Affiliated Hospital of Hebei Engineering University, Handan, China, First Hospital of Qinhuangdao, Qinhuangdao, China, Qinhuangdao Maternal and Child Health Hospital, Qinhuangdao, China,
Abstract
Personalized neoadjuvant strategy in ER positive and HER2 negative breast cancer to increase BCS rate (PLATO): A prospective, multicenter, phase II clinical trial.Org: Seoul National University Hospital, Seoul National University College of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul National University Bundang Hospital,
Abstract
Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study.Org: Institut Català D'Oncologia, IDIBELL, Seoul National University Hospital, Cancer Research Institute, Aichi Cancer Center Hospital,
Abstract
Phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors.Org: The University of Texas HSC at San Antonio Cancer Therapy and Research Center,
Abstract
AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization.Org: Centre Hospitalier De L Ardenne, Libramont-Chevigny, Belgium, Hospital Universitario Arnau de Vilanova; GEICAM Spanish Breast Cancer Group, Lleida, Spain, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, START Madrid - Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, The Oncology Institute, Whittier, CA,
Abstract
Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD).Org: Kanagawa Cancer Center, Fukushima Medical University, School of Medicine, Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), National Cancer Center Hospital East, Kashiwa, Japan, Department of Breast Surgery, Shizuoka General Hospital,
Abstract
Phase 1 study (NCT04931823) of CPO100 (albumin bound docetaxel) in patients with advanced solid tumors.Org: Comp Cancer Ctr of Nevada, UCLA- Santa Monica, Comprehensive Cancer Centers of Nevada, Carolina BioOnology Institute,
Abstract
The microtubule-destabilizing agent AUS_001 as a candidate for glioblastoma therapy.Org: Australis Pharmaceuticals, Inc., Kiyatec, Inc., College of Medicine and Public Health, Adelaide Medical School, The University of Adelaide,
Abstract
TBCRC 058: A randomized phase II study of enzalutamide, enzalutamide with mifepristone, and treatment of physician’s choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769).Org: Memorial Sloan Kettering Cancer Center, University of Alabama at Birmingham, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, Dana-Farber Cancer Institute, Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC,
Abstract
Paclitaxel oral solution versus paclitaxel injection as second-line therapy in advanced gastric cancer: A randomized, open-label, non-inferiority phase 3 trial.Org: Ruijin Hospital, Shanghai Jiaotong University School of Medicine,
Abstract
Impact on chemotherapy induced peripheral neuropathy of nadunolimab, a first-in-class monoclonal antibody against IL1RAP, in patients with pancreatic cancer, with supportive mouse model data.Org: Department of Hematology, Oncology and Cancer Immunology, Medical Oncology Department-CHU Sart-Tilman, Department of Oncology. Experimental Cancer Therapy Unit, Hospital of LUHS Kauno Klinikos, Institute for Molecular Bioscience, The University of Queensland,
Abstract
A phase I/II study of intraperitoneal (IP) paclitaxel (PTX) in patients with metastatic appendiceal adenocarcinoma.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX, Txinno Bioscience,
Abstract
Safety of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in patients (pts) with biliary tract cancer with peritoneal metastases.Org: City of Hope Comprehensive Cancer Center, Duarte, CA, CanSino Biologics,
Abstract
ODM-209, a CYP 11A1 inhibitor in patients with mCRPC: Results from the STESIDES phase 1 study.Org: Rigshospitalet University Hospital of Copenhagen, HUCH, Finland, Tampere University Hospital (TAYS), Espoo,
Abstract
Efficacy and safety of fruquintinib-based treatment in patients with refractory bone and soft tissue sarcomas after developing resistance to several TKIs: A multicentered retrospective study.Org: Department of Orthopaedics, Zhejiang University, Hangzhou, China, Musculoskeletal Tumor Center, Peking University People’s Hospital, Beijing, China, Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China, Peking University People’s Hospital, Beijing, China,
Abstract
Phase 1 study of anti–immunoglobulin-like transcript 3 (ILT3) monoclonal antibody MK-0482 + pembrolizumab + gemcitabine + nab-paclitaxel (Gem/Nab-P) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).Org: Ramat Gan, Hadassah Hebrew - University Medical Center, Jerusalem, Medical Oncology and Immunotherapy, Siena,
Abstract
A phase II study of anlotinib plus albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or peritoneal carcinomar (A-Plus trial): Updated efficacy and safety.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Department of Gynecologic Oncology, Gynecology and Obstetrics Center, The First Hospital of Jilin University, Changchun, China, Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine,
Abstract
Efficacy from the phase 1 study of FID-007, a novel nanoparticle paclitaxel formulation, in patients with head and neck squamous cell carcinoma.Org: Norris Comprehensive Cancer Center, University of Southern California Marshall School of Business, Fulgent Pharma,
Abstract
S1701: A randomized phase II trial of carboplatin-paclitaxel with and without ramucirumab in patients with locally advanced, recurrent, or metastatic thymic carcinoma.Org: Sugar Land, TX, NewYork-Presbyterian Hospital/Weill Cornell Medicine,
Abstract
Safety and tolerability of durvalumab + carboplatin/paclitaxel followed by durvalumab ± olaparib in patients with newly diagnosed advanced or recurrent endometrial cancer (EC) in the DUO-E/GOG-3041/ENGOT-EN10 trial.Org: Minnesota Oncology, Maplewood, MN, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL, FirstHealth Moore Regional Hospital, Pinehurst, NC, Oklahoma Cancer Specialists and Research Institute, Tulsa, OK, Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea,
Abstract
Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase 2 study.Org: Affiliated Zhenjiang Hospital of Jiangsu University, National Institute of Healthcare Data Science,
Abstract
A phase III randomized trial of eribulin (E) with gemcitabine (G) vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937 updated design.Org: Davis Comprehensive Cancer Center, Swog Gu Bladder Patient Advocate,
Abstract
Neoadjuvant immuno-chemo-radiotherapy in operable esophageal and gastroesophageal junction adenocarcinoma with carboplatin, paclitaxel plus radiotherapy and avelumab (anti-PDL1 antibody): Neo-CREATE trial.Org: Wollongong Hospital, Genesis Care, Bowel Health Service,
Abstract
TOURMALINE: A phase 3b study of durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer.Org: Vall d’Hebron Institute of Oncology (VHIO); Vall d’Hebron University Hospital, Statistics, DaneStat Consulting Limited, Oncology Business Unit Medical, AstraZeneca, Oncology Biostatistics Unit, AstraZeneca, Global Medical Affairs, AstraZeneca,
Abstract
FG-M108 plus nab-paclitaxel and gemcitabine (AG) as first-line (1L) treatment for patients with Claudin-18.2 (CLDN18.2) positive locally advanced unresectable or metastatic pancreatic cancer (PC): Preliminary results from the phase 1b study.Org: Phase I Clinical Trials Center, The First Hospital of China Medical University,
Abstract
Tisotumab vedotin in 2L/3L recurrent or metastatic cervical cancer: Subsequent therapy data from ENGOT-cx12/GOG-3057/innovaTV 301.Org: Broward Health, Genmab US, Inc.,
Abstract
Alliance A022106: A phase II/III trial of NABPLAGEM vs nab-paclitaxel/gemcitabine as second-line treatment for BRCA1/2 or PALB2 mutant metastatic pancreatic ductal adenocarcinoma (PLATINUM).Org: Department of Quantitative Science Research, Mount Sinai Comprehensive Cancer Center, University of California, San Diego Moores Cancer Center, Inova Fairfax Medical Campus, Department of Medicine, Section of Hematology and Oncology, University of Chicago,
Abstract
Neoadjuvant tislelizumab plus chemotherapy followed by salvage surgery and adjuvant tislelizumab for recurrent head and neck squamous cell carcinoma after radiotherapy: A single-arm, phase II trial.Org: Peking University School and Hospital of Stomatology, Beijing, China, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China,
Abstract
Duvelisib with docetaxel for patients with anti-PD-1 refractory, recurrent, or metastatic head and neck squamous cell carcinoma.Org: International Breast Cancer Study Group Statistical Center, Center for Head & Neck Oncology,
Abstract
Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A prospective, single-arm, open-label, phase 2 study.Org: National Clinical Research Centre for Cancer,
Abstract
Phase Ib INEOV neoadjuvant trial of durvalumab +/- tremelimumab with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): Survival outcomes and immune correlates.Org: UMR981 Institut Gustave Roussy, Confluent Private Hospital, Hôpital Cochin, Hôpital Européen Georges Pompidou, AP-HP.Centre – Université Paris Cité,
Abstract
A genetically engineered epothilone analog as a novel oral microtubule inhibitor: A clinical study of utidelone capsule for advanced breast cancer.Org: National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Beijing Biostar Pharmaceuticals Co., Ltd., Beijing, China,
Abstract
Expert consensus recommendations on the daily clinical use of pembrolizumab for early triple-negative breast cancer.Org: Chinese University of Hong Kong Medical Centre, Department of Medicine, The University of Hong Kong, United Christian Hospital, Hong Kong Baptist Hospital, Kwong Wah Hospital,
Abstract
Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: A single-centre retrospective study.Org: Fujian Normal University, Department of Breast Oncology, Fujian Cancer Hospital, Department of Oncology, Fujian Medical University Union Hospital, Department of Breast Medical Oncology, Fujian Cancer Hospital, Fuzhou University,
Abstract
REJOICE-Ovarian01: A phase 2/3 study of raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer (OVC).Org: Section of Gynecologic Oncology,
Abstract
Xevinapant with radiation and concurrent carboplatin and paclitaxel in patients ineligible for cisplatin with locoregionally advanced squamous cell carcinoma of the head and neck (EXtRaCT study)Org: The University of Chicago Medicine Center for Advanced Care at Orland Park, University of Michigan,
Abstract
A randomized phase II trial of atezolizumab with or without tiragolumab before and after definitive chemoradiation for unresectable stage III non-small cell lung cancer (NSCLC; AFT-57).Org: Rush University Cancer Center, Ideker Laboratory, Alliance Foundation Trials,
Abstract
Treatment (Tx) patterns, efficacy and safety of eribulin for advanced and heavily pretreated breast cancer (ABC): Updated results from a single-center, real-world study.Org: Jiaotong University,
Abstract
eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell (TC) expression <50%.Org: Hospital del Mar-CIBERONC, Institute Curie,
Abstract
A randomized, multi-center, phase 2 study of ivaltinostat (Ival) plus capecitabine (Cape) versus capecitabine alone in the maintenance setting in patients with metastatic pancreatic adenocarcinoma (mPDAC).Org: Clinical Research Alliance, LSU School of Medicine, CG Pharmaceuticals Inc.,
Abstract
Prediction for major pathologic response after neoadjuvant tislelizumab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma by RNA sequencing: A single-arm, phase II trial.Org: Daping Hospital, Army Medical University,
Abstract
Anlotinib plus docetaxel in advanced NSCLC progressing on immunotherapy: A pooled analysis of two randomized trials.Org: The Affiliated People’s Hospital of Ningbo University, The First Affiliated Hospital of Hunan College of Traditional Chinese Medicine, First People’s Hospital of Chenzhou, Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, The Affiliated Cancer Hospital of Xiangya Medical School, Central South University,
Abstract
Neoadjuvant chemo-immunotherapy following concurrent immuno-chemoradiotherapy and immune-maintenance therapy as primary treatment for locally advanced cervical cancer: A prospective, single-arm, phase 2 trial.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China,
Abstract
Datopotamab deruxtecan (Dato-DXd) in Chinese patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Results from the phase 1/2 TROPION-PanTumor02 study.Org: Jiangxi Provincial People's Hospital,
Abstract
Sequential neoadjuvant chemotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.Org: Atrium Health Wake Forest University Baptist Medical Center,
Abstract
Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [177Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603).Org: Department of Theranostics and Nuclear Medicine, Cancer Imaging, Prostate Cancer Theranostics and Imaging Centre of Excellence, Perth, Western Australia, Australia, ANZUP Cancer Clinical Trials Group,
Abstract
Conversion surgery for tislelizumab combined chemotherapy for T4a/N3 esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II study.Org: Department of Endoscopy, Department of Esophageal Minimal Invasive Surgery,
Abstract
Single agent axitinib in the management of patients with progressive pheochromocytoma and paraganglioma.Org: James J. Peters VAMC, Genitourinary Malignancies Branch, NCI, National Institutes of Child Health and Human Development, Clinical Pharmacology Program,
Abstract
Triage of advanced cervical cancer through immunotherapy induction (TRACTION).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX,
Abstract
Effectiveness and safety of disitamab vedotin (RC48) in pretreated HER2-positive advanced breast cancer: A real-world experience in China.Org: National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Internal Medicine-Oncology, Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, Shanxi Provincial Cancer Hospital, Taiyuan, China,
Abstract
A phase II trial to evaluate the epithelial-to-mesenchymal (EMT) inhibitor sotevtamab combined with docetaxel in patients with metastatic non-small cell lung cancer following failure of primary chemoimmunotherapy.Org: Hematology-Oncology Division, University of Montreal Health Centre (CHUM), Montréal, QC, Canada, CISSS des Laurentides, St Jerome, QC, Canada, Hopital Maisonneuve-Rosemont, Montreal, QC, Canada, Institut universitaire de cardiologie et de pneumologie de Québec - IUCPQ, Quebec, QC, Canada, Institut de recherche en immunologie et en cancérologie · IRIC, Montreal, QC, Canada,
Abstract
Efficacy and safety of luveltamab tazevibulin vs investigator’s choice of chemotherapy in patients with recurrent platinum-resistant ovarian cancer (PROC) expressing folate receptor alpha (FRα): The REFRaME-01 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase 2/3 study.Org: Medical Oncology Service, Vall d’Hebron Institute of Oncology, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain, Yonsei Cancer Center and Severance Hospital, Seoul, South Korea, Department of Gynaecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, The Royal Hospital for Women, Sydney, Australia, Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA,
Abstract
A propensity-matched cohort study of neoadjuvant immunotherapy combined with chemotherapy versus neoadjuvant chemotherapy for early-stage triple-negative breast cancer.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd.,
Abstract
A novel oral microtubule inhibitor utidelone capsule (UTD2): A phase 1 clinical study to assess the tolerability, safety, and efficacy in advanced solid tumors.Org: Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, Washington University in St. Louis, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Beijing Biostar Pharmaceuticals, Biostar Pharma,
Abstract
Prediction of therapeutic response and cancer outcomes in solid tumours via in silico clinical trials.Org: Concr LTD, Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow,
Abstract
Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III NSCLC (TRAILBLAZER): Efficacy, safety and feasibility of surgical conversion outcomes from a proof-of-concept, phase 2 trial.Org: Zhengzhou, China, Tianjin Medical University Cancer Institute and Hospital/National Clinical Research Center for Cancer, Luoyang, China, Hunan Provincial Tumor Hospital, Changsha, China,
Abstract
LUNAR-2: Pivotal, randomized, open-label study of tumor treating fields (TTFields, 150 kHz) concomitant with pembrolizumab and platinum based chemotherapy for the treatment of metastatic non-small cell lung cancer.Org: Franciscan Health Indianapolis,
Abstract
A phase II trial of AZD1775 plus carboplatin-paclitaxel in squamous cell lung cancer (SqCLC).Org: Moffit Cancer Center,
Abstract
Trastuzumab, pertuzumab and nab-paclitaxel plus pyrotinib or not in neoadjuvant treatment of HER2-positive breast cancer: A multi-center, randomized, open-label, phase II study.Org: Shangyu People's Hospital, Shaoxing, China,
Abstract
Radiation therapy (RT)-free pembrolizumab plus chemotherapy (P+C) for PD-L1 TPS ≥50% locally advanced non-small cell lung cancer (LA-NSCLC): Primary analysis from multicenter single arm phase II study (Evolution trial; WJOG11819L).Org: Department of Respiratory Medicine, NHO Nagoya Medical Center,
Abstract
A prospective phase II study of neoadjuvant therapy guided by personalized drug-testing on patient-derived tumor-like cell clusters for early breast cancer.Org: College of Future Technology Peking University, Peking University People's Hospital Breast Center,
Abstract
Alisertib in patients with extensive-stage small-cell lung cancer: The phase 2 ALISCA-Lung1 study.Org: Puma Biotechnology Inc.,
Abstract
Acupuncture for preventing progression of taxane-induced peripheral neuropathy (ATP): A phase II randomized, placebo-controlled trial.Org: Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY,
Abstract
A phase 3 global study of telisotuzumab vedotin versus docetaxel in previously treated patients with c-Met 0verexpressing, EGFR wildtype, locally advanced/metastatic nonsquamous NSCLC (TeliMET NSCLC-01).Org: Department of Shanghai Lung Center, Ospedale San Giovanni Addolorata,
Abstract
Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (DEP CTX) in patients with advanced solid cancers in a phase 1/2 trial (P1/2).Org: King's College London, Imperial College, University College London Cancer Institute, University College London Hospital NHS Trust and Great Ormond Street Hospital, Kinghorn Cancer Centre,
Abstract
Neoadjuvant chemotherapy with albumin-bound paclitaxel plus cisplatin and capecitabine for locally advanced esophageal squamous cell carcinoma: A prospective phase II trial.Org: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Science,Peking Union Medical College,
Abstract
Updated results of perioperative PD-1 antibody toripalimab plus FLOT chemotherapy for locally advanced resectable gastric or gastro-esophageal junction adenocarcinoma: A one-arm open-table phase II trial.Org: Tianjin Medical University Institute & Hospital, Department of GI Medical Oncology, Department of Cancer Center,
Abstract
Outcome with pertuzumab, docetaxel, and trastuzumab (PTH) regimen in patients with HER2 positive metastatic breast cancer: Real-world data from a single center in India.Org: Associate Consultant,
Abstract
Neoadjuvant therapy of camrelizumab combined with chemotherapy in patients (pts) with resectable esophageal squamous cell cancer (ESCC): A single-center, single-arm, exploratory clinical trial.Org: The Affifiliated Hospital of Qingdao University,
Abstract
Risk prediction model for taxane-induced peripheral neuropathy (TIPN) in patients with early-stage cancer receiving taxane therapy: SWOG S1714.Org: Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, SWOG Statistics and Data Management Center/Fred Hutchinson Cancer Research Center, University of Michigan Rogel Cancer Center, University of Michigan College of Pharmacy,
Abstract
Update results of anlotinib plus TQB2450 (PD-L1 blockade) combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer: A single-arm, open-label phase II clinical trial.Org: Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, China, The First Affiliated Hospital of Zhengzhou University, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
Atezolizumab plus taxane chemotherapy for the treatment of non-BRAF, non-RAS mutated anaplastic thyroid carcinoma: Final analysis.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Clinical outcomes of patients with HER2-positive microinvasive breast cancer.Org: Department of Oncology, National Taiwan University Hospital, Asan Medical Center, University of Ulsan College of Medicine, Division of Breast Surgery, Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV,
Abstract
Envafolimab plus chemotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II study.Org: Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Tangdu Hospital, Air Force Military Medical University, Xi'an, China,
Abstract
Tislelizumab combined with nab-paclitaxel single-agent chemotherapy plus bevacizumab for patients with EGFR-TKIs-resistant advanced NSCLC with ECOG PS 0-2.Org: National Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital, Guangzhou Medical University, Department of Respiratory Medicine, the First Affiliated Hospital of Guangzhou Medical University, Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health,
Abstract
Albumin-bound paclitaxel, cisplatin, and bleomycin combination with tislelizumab for stage IV squamous cell carcinoma of the penis without surgical indications: A single-arm, single-center prospective phase II clinical study.Org: Cancer Hospital of HuanXing ChaoYang District Beijing,
Abstract
Impact of concurrent antibiotics on survival with immunotherapy in metastatic colorectal and pancreatic cancer.Org: BC Cancer-Vancouver Centre, Canadian Cancer Trials Group, Queen's University Belfast, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada, Princess Margaret Cancer Centre,
Abstract
Response-adaptive resection following neoadjuvant penpulimab combined with chemotherapy in HPV-negative operable locally advanced head and neck squamous cell: A phase II clinical trial.Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Wuhan YZY Biopharma,
Abstract
Combination treatment effect of an immunotherapeutic agent with microtubule inhibitors.Org: Marshall B. Ketchum University, Molecular Pharmacology Branch,
Abstract
A prospective, open-label, single-arm phase II clinical study of inetetamab in combination with pyrotinib and albumin-bound paclitaxel for the neoadjuvant treatment of patients with HER2+ early and locally advanced breast cancer.Org: Department of Thyroid, Breast, and Vascular Surgery at Xijing Hospital, Air Force Medical University,
Abstract
AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC): A single-arm, open-label, multicenter, phase Ib study.Org: Department of Gastroenterology and Urology,
Abstract
Efficacy, safety and DNA methylation analysis of cadonilimab combined with taxane and cisplatin as the first-line treatment in patients with advanced esophageal squamous cell carcinoma (ESCC): An open-label, multicenter phase II trial– Updated results from AK104-IIT-014.Org: Department of VIP Medical Services,
Abstract
Durvalumab plus gemcitabine/cisplatin/nab-paclitaxel in resectable biliary tract cancer: A phase II, single-arm, open-label study (DurGAP).Org: Department of Hepatobiliary and Pancreatic Oncology, Tianjin Cancer Hospital Airport Hospital, Tianjin, China,
Abstract
Analysis of the efficacy and tolerance or darolutamide in combination with chemotherapy and ADT in patients with metastatic castration-sensitive prostate cancer (mCSPC) in the Spanish population in a daily clinic.Org: Hospital Guadalajara, Hospital General De Segovia, Hospital de Segovia, Hospital de Guadalajara,
Abstract
4CAST: A phase 1b dose exploration, open-label, single-center study evaluating the safety of INO-464 in combination with chemotherapy in patients with metastatic breast cancer.Org: The Kinghorn Cancer Centre, St. Vincent’s Hospital, Sydney, NSW, Australia, St. Vincent's Hospital, Darlinghurst, NSW, Australia,
Abstract
The efficacy and safety of trastuzumab biosimilar HLX02 compared with reference trastuzumab plus pertuzumab in combination with chemotherapy as the first-line treatment for HER2 positive metastatic breast cancer: A real-world study in China.Org: Peking University Cancer Hospital & Institute, Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China,
Abstract
Systematic literature review and network meta-analysis of first-line therapies for locally advanced/metastatic urothelial carcinoma.Org: Curta Inc.,
Abstract
Update results of anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China,
Abstract
Phase II randomized clinical trial comparing albumin-bound docetaxel vs. docetaxel in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.Org: Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China, The Eastern Hospital of the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Tianjin Medical University Cancer Institiute and Hospital, Tianjin, China, Department of VIP Medical Services, Shanxi Province Cancer Hospital, Shanxi, China, Fujian Cancer Hospital, Fuzhou, China, Jilin Cancer Hospital, Changchun, China, Affiliated Cancer Hospital of Harbin Medical University, Harbin, China, Meizhou People's Hospital, Meizhou, China, Hunan Cancer hospital, Changsha, China, Linfen City People's Hospital, Linfen, China, Sichuan Provincial People's Hospital, Chengdu, China, Yunnan Cancer Hospital, Kunming, China, Henan Cancer Hospital, Zhengzhou, China, The First Affiliated Hospital of Xiamen University, Xiamen, China, Gansu Provincial Cancer Hospital, Lanzhou, China, Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China, Changzhi People's Hospital, Changzhi, China, CSPC ZhongQi Pharmaceutical Technology Co., Ltd, Shijiazhuang, China, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China,
Abstract
Eribulin and irinotecan for refractory or recurrent Ewing sarcoma: A retrospective study.Org: Peking University People’s Hospital, Beijing, China,
Abstract
A randomized, controlled, multicenter, phase 3 study of vusolimogene oderparepvec (VO) combined with nivolumab vs treatment of physician’s choice in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3).Org: UPMC Hillman Cancer Center, Pittsburgh, PA, Replimune, Inc., Woburn, MA, Gustave Roussy and Paris-Saclay University,
Abstract
Efficacy and safety of PD-1 inhibitors plus metronomic oral vinorelbine in elderly pre-treated patients with metastatic non-small-cell lung cancer.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
First-line TQB2450 plus anlotinib combined with paclitaxel and cisplatin for advanced esophageal squamous cell carcinoma (ESCC): Update results of a multicenter phase II trial.Org: Department of Medical Oncology, Anyang Cancer Hospital, Anyang, China,
Abstract
Repurposing hemostatic drug desmopressin in AVPR2-expressing triple-negative breast cancer: Target expression analysis and preclinical antineoplastic effects on tumor growth and metastatic progression.Org: Center of Translational Medicine, El Cruce “Néstor Kirchner” Hospital, Montefiore Einstein Comprehensive Cancer Center/Albert Einstein College of Medicine, Center for Molecular and Translational Oncology (COMTra), Science and Technology Department, National University of Quilmes, Provincial Institute for Cancer Prevention and Treatment (IPC),
Abstract
Induction chemotherapy with nab-paclitaxel plus nedaplatin plus concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: A retrospective real-world study.Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou Yirui Pharmaceutical Technology, Zhejiang ACEA Pharmaceutical, China National Biotec Group,
Abstract
Interim results from a prospective multicenter phase II trial of stratified treatment of localized cervical esophageal squamous cell carcinoma induced by neoadjuvant immunotherapy plus chemotherapy (SCENIC trial).Org: Shanghai Chest Hospital, Jiaotong University, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital,
Abstract
First-line treatment patterns among patients with metastatic pancreatic ductal adenocarcinoma in the real-world setting.Org: Ipsen Biopharmaceuticals,
Abstract
Phase 3 randomized study for evaluation of physician choice Rx versus best supportive care as second-line or beyond therapy in head and neck cancer with poor performance status.Org: Sunrise Oncology Center,
Abstract
Neoadjuvant camrelizumab combined with chemotherapy for resectable stage IIIA-IIIb non-small cell lung cancer: Single arm phase II study.Org: Shandong Academy of Medical Sciences,
Abstract
A phase III randomized, double-blinded, placebo-controlled study of suvemcitug combined with chemotherapy for platinum-resistant ovarian cancer (SCORES).Org: State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China, Shanghai Xianxiang Medical Technology Co., Ltd, Shanghai, China,
Abstract
Metabolic changes due to dexamethasone premedication in patients with breast cancer.Org: ICESP,
Abstract
Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial, ALTER-G-001-cohort C.Org: Department of Oncology, Jiading Central Hospital, Shanghai, China, Department of Medical Oncology, Zhejiang Provincal People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China, Department of Oncology, Yancheng Third People's Hospital, Yancheng, China, Department of Oncology, Wuxi Branch of Ruijin Hospital, Wuxi, China, The Affiliated People’s Hospital of Ningbo University, Ningbo, China,
Abstract
De-escalation treatment of patients with HPV-positive oropharyngeal squamous cell carcinoma.Org: State Medical Institution "City Clinical Oncological Hospital № 1"," Moscow, Russian Federation, P. Hertsen Moscow Oncology Research Institute - Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation, Moscow, Russian Federation, City Clinical Cancer Hospital No. 1, Moscow, Russian Federation, Moscow City Clinical Oncology Hospital No. 1, Moscow, Russian Federation, State Medical Institution "S. Yudina Сity Clinical Hospital", Moscow, Russian Federation,
Abstract
Clinical efficacy and safety of mTOR inhibitor in patients with advanced unresectable epithelioid hemangioendothelioma (EHE).Org: Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China, National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up.Org: Biometrics Department, Department of Gynecological Oncology, Sint Antonius Hospital, Department of Gynecology and Obstetrics, Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV,
Abstract
Chemotherapy induced peripheral neuropathy (CIPN) due to paclitaxel versus docetaxel in patients with early-stage breast cancer receiving taxane therapy: SWOG S1714.Org: Fred Hutchinson Cancer Research Center, University of Michigan, Lewis Cancer & Research Pavilion at St. Joseph's Candler/GA NCORP, Bon Secours Cancer Institute at St. Francis, Cancer & Hematology Centers of Western Michigan,
Abstract
Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design.Org: Gustave Roussy Institute, Bergonié Institute, Léon Bérard Cancer Center, Institut de Cancérologie de l'Ouest, Azuréen Center of Oncology,
Abstract
Final results from phase I study of PSCA-targeted chimeric antigen receptor (CAR) T cells in patients with metastatic castration resistant prostate cancer (mCRPC).Org: City of Hope Comprehensive Cancer Center, City of Hope National Medical Center, City of Hope Beckman Research Institute, USC Norris Comprehensive Cancer Center, University of Southern California Marshall School of Business,
Abstract
Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).Org: University of Texas Southwestern Medical Center, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Duke University Cancer Institute, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Wake Forest Baptist Health,
Abstract
Analysis of healthcare provider treatment of advanced endometrial cancer and concordance with expert recommendations in 2023 vs 2022.Org: David Geffen School of Medicine at the University of California,
Abstract
Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC).Org: Memorial Sloan Kettering Cancer Center,
Abstract
A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC.Org: Stanford Cancer Center, Portuguese Oncology Institute of Porto, Porto, Portugal, The Kinghorn Cancer Centre, CUF Instituto de Oncologia, Macquarie University,
Abstract
Phase Ib study of talimogene laherparepvec (T-VEC) in combination with chemotherapy (CT) or endocrine therapy (ET) in patients with metastatic, unresectable, or locoregionally recurrent HER2-negative breast cancer (BC).Org: University of California, San Francisco, Division of Endocrinology, San Francisco, CA, University of California San Francisco, UCSF Medical Center, Helen Diller Family Comprehensive Cancer Center, University of California Comprehensive Cancer Center,
Abstract
Plinabulin to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant.Org: Adult Bone Marrow Transplant Service, Department of Medicine, Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, Myeloma Service, BeyondSpring Pharmaceuticals, Inc.,
Abstract
A phase 2 randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): ELEVATE-TNBC.Org: Cairns and Hinterland Hospital and Health Service, Cancer Research South Australia (CRSA), Queen Mary Hospital, Gilead Sciences, Inc., Gilead Sciences Inc,
Abstract
Long-term outcomes of adolescents and young adults with testicular germ cell tumors: A population-based retrospective matched cohort study.Org: The Hospital for Sick Children Research Institute, Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, Cancer Research Program, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada, ICES, Toronto, ON, Canada, Institute for Clinical Evaluative Science, Toronto, ON, Canada, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia,
Abstract
Plasma lipidomic profiling of chemotherapy-induced peripheral neuropathy.Org: Garvan Institute of Medical Research, Brain and Mind Centre, The University of Sydney, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Prince of Wales Hospital,
Abstract
A prospective, phase II, neoadjuvant clinical study based on chemotherapy sensitivity in hormone receptor–positive, HER2-negative breast cancer: FINEST study.Org: Fudan University Shanghai Cancer Center, Shanghai Cancer Center, Shanghai, China, Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University, Shangai, China, Jiangsu Hengrui Pharmaceuticals Co., Ltd.,
Abstract
Lisavanbulin in patients with recurrent glioblastoma: Phase 2a results and a consolidated analysis of response-predictive biomarkers.Org: The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Inselspital, Bern University Hospital, University of Bern, Department of Medical Oncology, Newcastle University and Northern Centre for Cancer Care, Freeman Hospital, UZ Leuven - Leuven Cancer Institute - KU Leuven, University Hospital Basel and University of Basel,
Abstract
The ARETHA study: A phase 2 randomized control trial of eribulin with evexomostat (SDX-7320) or placebo for patients with metastatic triple-negative breast cancer (TNBC) and metabolic dysfunction.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Efficacy and safety of tenalisib, a PI3K δ/γ and SIK3 inhibitor, in patients with locally advanced or metastatic breast cancer: Updated results from an on-going phase II study.Org: LTD High Technology Hospital Med Center, Batumi, Georgia, LLC Caucasus Medical Center, Simon Khechinashvili University Hospital, Rhizen Pharmaceuticals AG,
Abstract
A phase 1 dose escalation/expansion study of FID-007, a novel nanoparticle paclitaxel formulation, in patients with solid tumors.Org: University of Southern California Marshall School of Business, Norris Comprehensive Cancer Center, Fulgent Therapeutics, ANP Technologies, Inc,
Abstract
Hypersensitivity reaction to taxanes following COVID-19 vaccination.Org: Cleveland Clinic Foundation, Cleveland Clinic Taussig Cancer Instititute,
Abstract
Nationwide implementation of best practices in pancreatic cancer care (PACAP-1): Stepped-wedge cluster randomized trial.Org: Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands, University of Amsterdam, Netherlands Comprehensive Cancer Organisation (IKNL), Department of Surgery, Brigham and Women's Hospital, Boston, MA, Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Hokkaido, Japan,
Abstract
Neoadjuvant tislelizumab combined with APF for patients with locally advanced head and neck squamous cell carcinoma: A prospective single-arm clinical trial.Org: The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University,
Abstract
Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in patients with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC).Org: University of Pennsylvania, Stanford Cancer Center,
Abstract
Nab-paclitaxel plus cisplatin versus docetaxel plus cisplatin and 5-FU induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: A multicenter parallel controlled phase III trial.Org: Sun Yat-sen University Cancer Center Gansu Hospital, The 5th Affiliated Hospital of Sun Yat-sen University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Department of Nasopharyngeal Carcinoma, The First People's Hao Cheng Hospital of Chenzhou, Southern Medical University, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China,
Abstract
Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial.Org: Washington University School of Medicine in St Louis, Natco Pharma, NATCO Pharma Limited,
Abstract
Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001.Org: City of Hope National Medical Center, Fred Hutchiinson Cancer Research Center, SWOG Statistics and Data Management Center, Seattle, WA, Johns Hopkins University School of Medicine, University of Pennsylvania,
Abstract
MyTACTIC: Afficacy and safety of atezolizumab (atezo) + chemotherapy (chemo) in patients (pts) with advanced unresectable/metastatic solid tumors with high tumor mutational burden (TMB-H) or high microsatellite instability (MSI-H)/deficient mismatch repair (dMMR).Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, OneOncology, Inc., New York Cancer and Blood Specialists,
Abstract
Novel STK11 differentiation phenotype classifier STK11-DPC: Immunosuppressive tumor microenvironment (TME) and response to immune checkpoint blockade (ICB) in STK11-deficient NSCLC.Org: The James Cancer Hospital and Solove Research Institute, Ohio State University Comprehensive Cancer Center, Ohio State University Comprehensive Canvcer Hospital, The Ohio State University - James Cancer Hospital, The Ohio State University Wexner Medical Center,
Abstract
Molecular and clinical correlates of DSCR1 expression in pancreatic cancer (PDAC).Org: Caris Life Sciences, Irving, TX, West Virginia University Cancer Institute, Mary Babb Randolph Cancer Center, Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center,
Abstract
The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC).Org: Duke University Medical Center, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, MRC Clinical Trials Unit at UCL, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, SWOG Statistical Center,
Abstract
Neoadjuvant docetaxel, oxaliplatin, and s-1 plus surgery and adjuvant s-1 for resectable advanced gastric cancer: Final survival outcomes of the randomized phase 3 PRODIGY trial.Org: Asan Medical Center, Chonnam National University Hwasun Hospital, National Cancer Center Hospital East, Kashiwa, Japan, Keimyung University Dongsan Hospital, Yonsei Cancer Center, Yonsei University Health System,
Abstract
Oregovomab and non-platinum chemotherapy in PARP inhibitor-resistant ovarian, fallopian tube, or primary peritoneal cancer patients not candidates for platinum retreatment: A multicenter, two-cohort, single-arm phase 2 trial (OPERA/KGOG 3065/APGOT-OV6).Org: Yonsei University College of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea University College of Medicine, Seoul National University Bundang Hospital,
Abstract
A phase Ib trial of the VEGF fusion protein HB002.1T plus chemotherapy in patients with advanced solid tumors.Org: Huaota Biopharma Co., Ltd., Shanghai, China, Huaota Biopharm Co., Ltd., Shanghai, China, Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences,
Abstract
The significance of mucin on rectal MRI in patients with locally advanced rectal cancer being considered for watch-and-wait after neoadjuvant therapy.Org: Memorial Sloan Kettering Cancer Center, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, Department of Surgery, Brigham and Women's Hospital, Boston, MA,
Abstract
Radiation therapy (RT)-free pembrolizumab plus chemotherapy (P+C) for PD-L1 TPS ≥50% locally advanced non-small cell lung cancer (LA-NSCLC): An early report analyzing depth of response from multicenter single arm phase II study (Evolution trial: WJOG11819L).Org: Kobe Minimally Invasive Cancer Center, National Hospital Organization Nagoya Medical Center, Aichi, Japan, Takarazuka City Hospital, Hyogo Medical University, Kurashiki Central Hospital, Kurashiki, Japan,
Abstract
Deutenzalutamide, an oral deuterated androgen receptor inhibitor, vs placebo for patients with mCRPC who have experienced treatment failure with abiraterone and docetaxel: Results of the HC-1119-04 phase 3 trial.Org: Fudan University Shanghai Cancer Center, Jiangsu Province Hospital, The Second Hospital of Tianjin Medical University, Department of Uro-Oncology, Chongqing University Cancer Hospital, Sichuan Provincial People's Hospital, Chengdu, China,
Abstract
Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT).Org: Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands, University Medical Center Utrecht, Sotiria General Hospital, Azienda Ospedaliero Universitaria Careggi, University of Florence, Centre Hospitalier Universitaire de Liège,
Abstract
Anlotinib combined with carboplatin/paclitaxel and maintenance anlotinib as front-line treatment for newly diagnosed advanced ovarian cancer: A phase II, single-arm, multicenter study (ALTER-GO-010).Org: Jiangsu Province Hospital, Huai'an First People's Hospital, Nanjing Drum Tower Hospital, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China, Zhongda Hospital Southeast University,
Abstract
Association of HER2/CEP17 ratio with pCR after HER2-directed neoadjuvant treatments in the phase III NeoALTTO trial.Org: Comprehensive Cancer Center - Universitätsklinik für Frauenheilkunde Medizinische Universität Wien / AKH, Medical University of Vienna, Dept of OB/GYN, Karl Landsteiner Medical University, Department of Gynecology and Obstetrics, Medical University of Innsbruck, Innsbruck, Austria, Department of Oncology, Medical University of Graz,
Abstract
Trends and outcomes of systemic therapy in hormone receptor-positive early-stage male breast cancer: A propensity score analysis.Org: Department of Breast Surgery, Fujian Medical University Union Hospital, Fuzhou, China, Nosocomial Infection Control Branch, Fujian Medical University Union Hospital, Fuzhou, Fujian, China, Department of Breast Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, Fujian Province, 350001, China, Fujian Center for Disease Control and Prevention, Fuzhou, Fujian, China, Johns Hopkins University, Baltimore, MD,
Abstract
ASCEND: A randomised, double-blinded, phase II study of gemcitabine and nab‐paclitaxel with CEND‐1/LSTA1 or placebo in patients with untreated metastatic pancreatic ductal adenocarcinoma.Org: St. John of God Hospital Subiaco, Queen Elizabeth Hospital, University of Adelaide, Woodville, St. George Hospital,
Abstract
Are we ready for biomarker driven, radiation dose–adaptable de-escalation studies for HPV+ oropharyngeal cancer?Org: Hematology and Medical Oncology, Universitätsklinikum Jena, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Tisch Cancer Institute,
Abstract
Preliminary translational immune and stromal correlates in a randomized phase II trial of pembrolizumab with or without defactinib for resectable pancreatic ductal adenocarcinoma (PDAC).Org: Cedars-Sinai Medical Center, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Johns Hopkins University Bloomberg School of Public Health, Verastem, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA,
Abstract
An open-label window of opportunity trial to evaluate the activity of durvalumab and tremelimumab with platinum-based chemotherapy (gemcitabine and cisplatin) in intrahepatic cholangiocarcinoma.Org: Emory University School of Medicine, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, University of Alabama at Birmingham Department of Hematology, Birmingham, AL, Birmingham, AL, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan,
Abstract
Dosage optimization in drug development: An FDA Project Optimus analysis of postmarketing requirements issued to repair the cracks.Org: Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Oncology Center of Excellence,
Abstract
Ex vivo tumor testing platform for predicting clinical response to platinum-based therapy in patients with high grade serous ovarian cancer.Org: Radboud University Medical Center and Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands Cancer Institute, Leiden University Medical Center, Leiden University,
Abstract
Predicting role of circulating tumor DNA and blood-based tumor mutational burden in esophageal squamous cell carcinoma receiving chemoradiotherapy combined with toripalimab: Exploratory analyses from a phase II trial (EC-CRT-001).Org: Sun Yat-sen University Cancer Center Gansu Hospital, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,
Abstract
Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin followed by adjuvant tislelizumab in patients with early triple-negative breast cancer.Org: Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China, Department of Breast Surgery, The Second Hospital of Shandong University, Jinan, China, Department of Breast Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, Department of Breast Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China, Department of Breast Surgery, Henan Cancer Hospital, Zhengzhou, China,
Abstract
Pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of malignant esophago-gastric diseases (PROCEED): Assessment of pathologic response and toxicity in a prospective, phase II single-arm trial.Org: Duke Cancer Institute, Duke University Medical Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC,
Abstract
An analysis to inform the timing of docetaxel use leveraging data from the United States Veterans Administration on patients with metastatic castration-sensitive prostate cancer (mCSPC).Org: Columbia University Medical Center, University of Nebraska Medical Center, Institute of Molecular Biology, Bulgarian Academy of Sciences, Columbia University Herbert Irving Comprehensive Cancer Center, James Peters Bronx Veterans Affairs Medical Center,
Abstract
A phase I dose-escalation clinical trial with PLZ4-coated paclitaxel-loaded micelles (PPM) in patients with recurrent or refractory non-myoinvasive bladder cancer.Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, Brigham and Women’s Hospital, Harvard Medical School, Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, University of California Davis Comprehensive Cancer Center,
Abstract
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.Org: Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Maternal and Child Health Hospital of Jiangxi Province, Shandong Cancer Hospital & Institute, The Affiliated Tumor Hospital of Zhengzhou University, The First Affiliated Hospital of Soochow University,
Abstract
First trial of chemotherapy de-escalation in ovarian cancer (OC): A phase III randomized, open label study of niraparib maintenance after carboplatin and paclitaxel in patients with optimally debulked advanced (homologous recombination deficient) HRD high-grade ovarian cancer in first line therapy (N-PLUS/NOGGO-ov53/ENGOT-ov62).Org: Charite-Universitätsmedizin Berlin, Department of Gynecology with Center for Oncological Surgery, Campus Virchow Klinikum, Berlin, Germany, Stanford University School of Medicine, Institute for Biometry and Clinical Epidemiology, Hospital Universitario Virgen del Rocío, Sant'Anna Hospital,
Abstract
Tislelizumab plus chemotherapy as induction treatment followed by chemoradiotherapy or surgery in locally advanced hypopharyngeal squamous cell carcinoma: A single-arm, phase II trial.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Cancer Hospital of Chinese Academy of Medical Sciences,
Abstract
Induction therapy of toripalimab combined with docetaxel and cisplatin in locally advanced hypopharyngeal squamous cell carcinoma (HPSCC): A single-arm, phase II clinical trial.Org: Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China, Beijing InnoCare Pharma Tech, China National Biotec Group,
Abstract
Impact of genomic alterations measured in circulating tumor DNA (ctDNA) on clinical response to telisotuzumab vedotin treatment in patients with non-small cell lung cancer (NSCLC).Org: University of Colorado Cancer Center, University Hospital Birmingham NHS Foundation Trust, AbbVie Inc., North Chicago, IL, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, China,
Abstract
Induction chemotherapy and toripalimab for larynx preservation in resectable locally advanced laryngeal/hypopharyngeal carcinoma: Preliminary results of INSIGHT study.Org: Fudan University Shanghai Cancer Center, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Department of Head & Neck Tumors and Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, China,
Abstract
Results from two phase II studies of SI-B001, an EGFR×HER3 bispecific antibody, with/without chemotherapy in patients (pts) with recurrent and metastatic head and neck squamous cell carcinoma (HNSCC).Org: Shanghai East Hospital, Tongji University, Shanghai, China, Union Hospital, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China, Zhejiang Cancer Hospital, Chinese Academy of Sciences, West China Hospital, Sichuan University,
Abstract
A multi-cohort phase I/IIa clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 administered as a monotherapy, with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors: TransStar101.Org: Memorial Sloan Kettering Cancer Center, University of Kansas Medical Center Department of Internal Medicine, NSABP/NRG Oncology and Wake Forest University Baptist Medical Center, Gettysburg Cancer Center, University of Arizona Cancer Center,
Abstract
Cost-effectiveness analysis (CEA) of seven treatment regimens in metastatic hormone-sensitive prostate cancer (mHSPC): A public payer perspective using network meta-analysis.Org: Huntsman Cancer Institute at the University of Utah, University of Utah, Case Western Reserve University School of Medicine, University of Utah/Huntsman Cancer Institute,
Abstract
A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.Org: SWOG Statistics and Data Management Center, Seattle, WA, University of California Davis Comprehensive Cancer Center, Fred Hutchinson Cancer Research Center, SWOG Cancer Research Network, Baylor College of Medicine,
Abstract
waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL).Org: Hadassah Medical Center, Ankara University School of Medicine, Maria Sklodowska-Curie National Research Institute of Oncology, Institut Català d'Oncologia Hospitalet, Samsung Medical Center,
Abstract
PRESERVE-003: Phase 3, two-stage, randomized study of ONC-392 versus docetaxel in metastatic non-small cell lung cancers that progressed on PD-1/PD-L1 inhibitors.Org: AdventHealth Cancer Institute, Orlando, FL, James Thoracic Oncology Center, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, University of California Davis Comprehensive Cancer Center, OncoC4,
Abstract
LUNG-IST-127: A pilot phase II study of maintenance cabozantinib plus pembrolizumab for patients with metastatic squamous non-small cell lung cancer (sqNSCLC) with disease control following induction therapy.Org: Department of Hematology Oncology University of Illinois of Chicago College of Medicine, University of Ilinois Chicago, Department of Surgery University of Illinois of Chicago College of Medicine, University of Illinois Chicago, Jesse Brown VAMC,
Abstract
Efficacy and safety of polymeric micelle paclitaxel (pm-Pac) plus tislelizumab and carboplatin for first-line treatment of patients with advanced squamous non-small-cell lung cancer.Org: Department of Medical Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, China, Departments of Radiation Oncology and Medical Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, China, Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China,
Abstract
Skin adverse events of anti-cancer treatments: An examination of drug-AE associations.Org: La Roche-Posay International, Levallois-Perret, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, Memorial Sloan Kettering Cancer Center,
Abstract
Efficacy and safety of eribulin as a front-line treatment in patients with advanced breast cancer: The first large scale prospective real-world study in China.Org: Sun Yat-sen Memorial Hospital of SunYat-sen University, Guangzhou, China, Sun Yat-sen University Cancer Center Gansu Hospital,
Abstract
Cardiac safety of reduced surveillance for cancer therapy related cardiac dysfunction in patients with breast cancer treated with HER2-targeted therapy.Org: Memorial Sloan Kettering Cancer Center, Hartford Healthcare Medical Group, Hartford Healthcare Cancer Institute, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC,
Abstract
Optimization of a deep convolution neural network (DCNN) for osteosarcoma necrosis quantification and outcome prediction.Org: NYU School of Medicine, New York University Langone Medical Center, Applied Bioinformatics Laboratories, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,
Abstract
Evaluating the efficacy and safety of pembrolizumab monotherapy or in combination with standard chemotherapy in the first-line treatment of locally recurrent head and neck squamous cell carcinoma in different TP53 and PI3K statuses.Org: Beijing Tongren Hospital, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China,
Abstract
A meta-analysis studying the utility of cryotherapy in the prevention of peripheral neuropathy in breast cancer patients receiving paclitaxel and nab-paclitaxel.Org: Upstate University Hospital, SUNY Upstate Medical University, State University of New York Upstate Medical University,
Abstract
Pegylated liposomal doxorubicin and carboplatin versus paclitaxel and carboplatin as first-line treatment for Chinese patients with ovarian cancer: A multi‑center, randomized, open‑label trial.Org: Women's Hospital School of Medicine Zhejiang University, Qilu Hospital of Shandong University, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, West China Second University Hospital,
Abstract
Phase 2 small cell lung cancer (SCLC) cohort of a phase 1b/2 trial of a liposomal formulation of eribulin in combination with nivolumab.Org: Kurume University Hospital, Kanagawa Cancer Center, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, National Hospital Organization Kinki-Chuo Medical Center, Osaka International Cancer Institute, Osaka, Japan,
Abstract
Time to treatment in inflammatory breast cancer: Experience from a single institution.Org: Ohio State University Wexner Medical Center, Center for Biostatistics in the Department of Biomedical Informatics, The Ohio State University - James Cancer Hospital, Ohio State University Comprehensive Canvcer Hospital,
Abstract
Efficacy of bi-weekly docetaxel in hormone-sensitive metastatic prostate cancer (mHSPC).Org: Centro Integral de Cancer-Clinica de Occidente, NALT MEDICAL SOLUTIONS, Clinica De Occidente,
Abstract
Therapeutic strategies for metaplastic breast cancer: A clinicopathologic analysis of a single institution cohort.Org: University of California San Diego Medical Center, La Jolla, CA, UC San Diego Moores Cancer Center,
Abstract
Two schedules of vincristine, irinotecan and temozolomide (VIT) for patients with relapsed or refractory Ewing sarcoma: A randomized controlled phase 2 trial.Org: Peking University People's Hospital, Beijing, China,
Abstract
Disparities in molecular tumor board recommendations and treatment implementation.Org: University of Virginia Health System, Inova Schar Cancer Institute, Inova Fairfax Hospital,
Abstract
Phase 2 clinical trial of the proautophagic drug ABTL0812 combined with paclitaxel and carboplatin in first-line patients with advanced squamous non-small cell lung carcinoma.Org: Catalan Institute of Oncology-Hospitalet, Hospital Josep Trueta, IDIBGi, Hospital Germans Trias i Pujol, IGTP (Health Research Institute Germans Trias i Pujol),
Abstract
Clinicopathological characteristics, treatment patterns, and prognosis of male breast cancer: China versus the United States.Org: Breast Disease Center, West China Hospital, Sichuan University, The First Affiliated Hospital of Sun Yat-sen University, The Fifth Medical Center of Chinese PLA General Hospital,
Abstract
Older patients with early-stage triple-negative breast cancer: The Memorial Sloan Kettering Cancer Center experience.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT).Org: Schulich School of Medicine and Dentistry, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, London Regional Cancer Program, University Health Network,
Abstract
Five-year overall survival with S-1 plus docetaxel as adjuvant treatment in curatively resected pStage III gastric cancer in JACCRO GC-07.Org: Division of Medical Oncology, Showa University Fujigaoka Hospital, Yokohama, Japan, Gifu University, Gifu, Japan, Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan, Department of Surgery, Shinshu University, Matsumoto, Japan, Department of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan,
Abstract
Homologous recombination deficiency (HRD) status to predict the efficacy and prognosis of platinum-based neoadjuvant chemotherapy in patients with triple-negative breast cancer.Org: Fujian Medical University Union Hospital, Amoy Diagnostics Co., Ltd.,
Abstract
The clinical value of homologous recombination deficiency score in prostate cancer.Org: Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China, Shanghai OrigiMed Co., Ltd, Shanghai, China, Shanghai OrigiMed Co., Ltd., Shanghai, China,
Abstract
Early taxane-induced neurotoxicity and quality of life in patients with breast cancer: A single center, retrospective study.Org: Medical Oncolgy Unit, University Hospital and University of Cagliari, University Hospital of Cagliari,
Abstract
Bioequivalence study of BH009 and Winthrop (docetaxel) injection (an authorized generic drug of Taxotere) in patients with advanced solid tumor: An open-label, randomized, single-dose, two-way crossover evaluation.Org: Zhuhai Beihai Biotech,
Abstract
Associations among anesthesia-induced brain biomarkers during surgery, preoperative exposure to cancer therapeutics, and clinical outcomes.Org: Massachusetts General Hospital, Beth Israel Deaconess Medical Center, The University of Oklahoma Stephenson Cancer Center,
Abstract
Combination of eribulin with trastuzumab and pertuzumab for HER2 positive advanced or recurrent breast cancer: JBCRGM03.Org: Kanagawa Cancer Center, Matsuyama Red Cross Hospital, Nagoya University Graduate School of Medicine, Asahikawa Medical University Hospital, Yokohama City University Medical Center, Yokohama, Japan,
Abstract
The use of minimal residual disease in patients with high-risk breast cancer.Org: John A Burns School of Medicine, University of Hawaii Cancer Center,
Abstract
Efficacy and safety of induction chemotherapy with docetaxel + cisplatin in selected groups of patients with HNSCC.Org: Pavlov University, Saint-Petersburg, Russian Federation, Saint-Petersburg State University, Medical Faculty Mannheim, SPb SBIH City clinical oncology dispensary,
Abstract
Continuous dosing of AUM001 with cyclical gemcitabine/nab-paclitaxel to maintain the tumor growth kinetics in KPC xenograft model.Org: National Cancer Centre Singapore, Singapore Immunology Network,
Abstract
INSIGHT-HER2BC: Real-world evidence of TCHP regimen to describe the best patient profile and open up questions—The interim results.Org: Moscow Clinical Scientific Center named after A.S. Loginov, Moscow Oncology City Hospital 62, SBIH Municipal Clinical Oncology Hospital №1 of DHM, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, RAS,
Abstract
Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer: A multi-center, open-label, single-arm, phase II study.Org: The Fifth Affiliated Hospital of Sun Yet-Sen University, Zhuhai, China, The First Affiliated Hospital of Guangxi Medical University, Nanning, China, Zhuhai Hospital of lntegrated Traditional Chinese and Western Medicine, Zhuhai, China, Department of Breast Surgery, Zhuhai Maternity and Child Health Hospital, Zhuhai, China, The First People's Hospital of Zhaoqing, Zhaoqing, China,
Abstract
Pathologic complete response in germline mutation carriers by mutation type and biomarkers in a safety-net population.Org: Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, Baylor College of Medicine, Southern California Permanente Medical Group,
Abstract
Phase II results of ivonescimab (AK112/ SMT112), a novel PD-1/VEGF bispecific, in combination with chemotherapy for first line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA) in EGFR/ALK.Org: Sun Yat-sen University Cancer Center, Guangzhou, China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China, Hunan Cancer Hospital, Changsha, China, Yunnan Cancer Hospital, Kunming, China, The First Affiliated Hospital of Anhui Medical University, Hefei, China,
Abstract
A comparative study evaluating the quality of life in patients receiving chemotherapy versus oral TKI in the third line and beyond setting for advanced non–small-cell lung cancer.Org: Tata Memorial Centre, Tata Memorial Hospital (HBNI),
Abstract
Clinical outcomes of patients with metastatic breast cancer treated with eribulin: A real-world evidence study from China.Org: West China Hospital, Sichuan University, Breast Disease Center, West China Hospital, Sichuan University, West China Hospital of Sichuan University,
Abstract
Impact of pre-treatment hemoglobin (Hgb) on outcomes in metastatic castration resistant prostate cancer (mCRPC) with lutetium-177-PSMA-617 (Lu-177).Org: The Medical College of Wisconsin, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,
Abstract
Efficacy of eribulin administered in combination with an immune checkpoint inhibitor (ICI) and anlotinib as salvage treatment for patients (pts) with advanced adult soft tissue sarcoma (STS).Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Effect of doxorubicin on efficacy of immune checkpoint inhibitors through increasing infiltration of CD8-positive T cells and activating STAT1-IRF1-CXCL10 axis.Org: Department of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China, Department of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, Shanghai/China, China, Department of Breast and Urinary Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, Shanghai/China, China,
Abstract
Anlotinib plus irinotecan or docetaxel in small-cell lung cancer (SCLC) relapsed within six months: Updated results from a single-arm, phase Ⅱ study.Org: Affiliated Hangzhou Cancer Hospital, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China, Hangzhou, Zhejiang, China, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Affiliated Hangzhou First People’s Hospital,
Abstract
Phase 2 study of weekly polymeric micelle-formulated paclitaxel plus gemcitabine in patients with recurrent and metastatic adenocarcinoma of the pancreas.Org: Ajou University Hospital, Haeundae Paik Hospital, Uijeongbu St. Mary's Hospital, St. Vincent’s Hospital, Uijeongbu Eulji Medical Center,
Abstract
Dendritic/histiocytic cell sarcoma: The OSU experience.Org: The Ohio State University - James Cancer Hospital, The Ohio State University - James Cancer Hospital and Solove Research Institute, Ohio State University Comprehensive Canvcer Hospital, The Ohio State University James Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH,
Abstract
Effects of treatment and patterns of metastases in upper tract and bladder urothelial cancer and non-urothelial cancer based on the National Cancer Database (NCDB) analysis.Org: Inova Schar Cancer Institute, Georgetown University Medical School,
Abstract
Survival of de novo metastatic hormone sensitive prostate cancer in US Veterans based on treatment and PSA at diagnosis.Org: Saint Louis University School of Medicine, University of Washington Medical Center, Fred Hutchinson Cancer Research Center, St. Louis University, Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine,
Abstract
Phase I/II study of nab-paclitaxel combined with S-1 as adjuvant chemotherapy in diffuse type of stage III gastric or gastroesophageal junction adenocarcinoma.Org: Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, China, Department of Oncology, Cancer center, Zhongshan Hospital, Fudan University, Shanghai, China,
Abstract
A real-world study of US patients with metastatic ovarian, fallopian tube, and peritoneal cancer (mOFPC) using integrated electronic health records (EHR) and claims datasets.Org: ConcertAI, Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC, Labcorp Drug Development Inc., Princeton, NJ,
Abstract
Defendor special: Interim analysis of TCHP with primary empegfilgrastim prophylaxis (long-acting G-CSF) for treatment outcomes in early HER2+ breast cancer.Org: Moscow Clinical Scientific Center named after A.S. Loginov, Russian Cancer Research Center N.N. Blokhin,
Abstract
Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in patients with high-risk UTUC.Org: The Second Hospital of Tianjin Medical University, Tianjin, China, Tianjin Medical University Second Hospital,
Abstract
SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Washington University School of Medicine in St Louis, Mayo Clinic, University of Washington and Fred Hutchinson Cancer Research Centre,
Abstract
A phase II study of weekly carboplatin and nab-paclitaxel with trastuzumab or bevacizumab as neoadjuvant therapy for patients with early-stage nonmetastatic breast cancer.Org: University of California, Irvine, Irvine, CA, UC Irvine Health, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Nepal Medical College and Teaching Hospital, Kathmandu Medical College and Teaching Hospital,
Abstract
Clinical implications of recurring mutations in myxoid liposarcoma (MLS).Org: University of Texas MD Anderson Cancer Center, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center,
Abstract
Real-world intensification beyond androgen deprivation therapy (ADT) in metastatic hormone sensitive prostate cancer (mHSPC) in the United States 2017-2023: An administrative claims database study.Org: Bayer HealthCare Pharmaceuticals Inc., Bayer AG, Bayer Ltd, Bayer Consumer Care AG, Duke Cancer Institute Center for Prostate and Urologic Cancers,
Abstract
The role of Chinese acupuncture plus herbal decoction for chemotherapy induced cognitive impairment in elderly cancer patients.Org: Jiangsu Health Vocational College, Liyang people‘s hospital, Nanjing 1st Hospital, Jingling Hospital, Nanjing Medical University,
Abstract
Preclinical testing of farletuzumab ecteribulin (FZEC [MORAb-202]) and MORAb-109, folate receptor α and mesothelin targeting antibody-drug conjugates (ADCs), in rare gynecologic cancers.Org: Walter and Eliza Hall Institute of Medical Research, The University of Melbourne, Eisai, Exton, School of Clinical Sciences at Monash Health,
Abstract
Impact of COVID-19 pandemic on the treatment of prostate cancer in the Brazilian Public Health System.Org: LACOG - Latin American Cooperative Oncology Group, University of California, San Diego (UCSD), University of California at San Diego, Univeristy of California San Diego, Hospital Beneficência Portuguesa de São Paulo, São Paulo, Brazil,
Abstract
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer.Org: University of Chicago, Northshore University Health System, Froedtert & Medical College of Wisconsin, University of Chicago Medical Center, Chicago, IL, Section of Hematology/Oncology,
Abstract
Urine DNA model to predict response to neoadjuvant immune checkpoint inhibitors combined with chemotherapy in muscle-invasive bladder cancer.Org: AcornMed Biotechnology Co., Ltd., Beijing, China,
Abstract
Comparison of two ICI-based microtubule antagonist therapies for high-risk, non-muscle-invasive bladder cancer.Org: The Second Hospital of Tianjin Medical University, Tianjin Hemay Pharmaceutical, Second Hospital of Tianjin Medical University,
Abstract
Obesity and toxic habits as avoidable determinants of chronic peripheral neuropathy induced by chemotherapy (NPCIQ): NeuroPredict project.Org: Reina Sofía University Hospital, Hospital Universitario Reina Sofía, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)–H. Universitario Reina Sofía, Universidad de Córdoba, GEICAM Spanish Breast Cancer Group, Barcelona, Spain, CIBERONC,
Abstract
Identifying care fragmentation in the management of non-metastatic muscle-invasive bladder cancer.Org: Hillman Cancer Center, Pittsburgh, PA, University of Pittsburgh Graduate School of Public Health, Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Division of Health Services Research, University of Pittsburgh Medical Center,
Abstract
Multi-omics analysis to reveal the change of peripheral blood TCR repertoire and tumor burden during neoadjuvant chemotherapy combined with sequential PD-1 blockade for patients with non-small cell lung cancers: A single-center, single-arm phase 2 trial.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Chinese PLA General Hospital, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, School of Medicine Nankai University,
Abstract
Pathologic complete response (pCR) to neoadjuvant treatment (NAT) with carboplatin, nab-paclitaxel and anthracycline in early and locally advanced triple-negative breast cancer (TNBC).Org: Medical Oncology Department, University Hospital Virgen del Rocío, Sevilla, Spain, Medical Oncology Department, University Hospital Puerto Real, Cádiz, Spain, Medical Oncology Department, University Hospital Virgen Macarena, Sevilla, Spain, University Hospital Virgen del Rocío, Sevilla, Spain, Hospital Virgen del Rocio de Sevilla. GEICAM Spanish Breast Cancer Group, Seville, Spain,
Abstract
Hearing loss related outcomes post-lateral temporal bone resection and other oncologic treatment.Org: University of Texas MD Anderson Cancer Center, UT Health San Antonio, MD Anderson Cancer Center, Associates of Audiology, LLC,
Abstract
Clinicopathological characteristics and survival outcomes for testicular choriocarcinoma and non-testicular choriocarcinoma: A SEER database analysis.Org: Jordan University of Science and Technology,
Abstract
Cryptococcosis in non-HIV/non-transplant hematological patients: A 12-year retrospective clinical analysis in a Peruvian referral cancer center.Org: Dana-Farber Cancer Institute, Instituto Nacional de Enfermedades Neoplasicas, Lima, 51, Peru, Universidad Nacional Mayor de San Marcos, Hospital das Clinicas UFMG,
Abstract
Randomized placebo-controlled trial of intravenous vitamin C plus docetaxel in metastatic prostate cancer.Org: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Karmanos Cancer Institute, Wayne State University School of Medicine,
Abstract
A single-institution analysis of a rare variant of pancreatic neoplasm-osteoclastic giant cell tumor.Org: University of Nebraska Medical Center, Omaha, NE,
Abstract
A retrospective real-world study of nimotuzumab combined with chemotherapy for advanced pancreatic cancer.Org: First Affiliated Hospital of Medical College of Xi’an Jiaotong University, Xi'an, China, Xi'an, shaanxi, China, China National Biotec Group,
Abstract
Reliance of agency-approved and guideline-recommended therapies on surrogate endpoints in triple-negative breast cancer (TNBC).Org: The Larvol Group, LLC, Labcorp Drug Development Inc., Princeton, NJ, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Trust,
Abstract
Additional cycles of docetaxel in combination with androgen deprivation therapy (D-ADT) in metastatic hormone-sensitive prostate cancer (mHSPC): Efficacy and feasibility analysis.Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, University Hospital 12 de Octubre, LMU Munich, Munich, Germany, Germany,
Abstract
Paclitaxel + ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs: Final results from the randomized phase 2 IKF-S627/RAMOS trial of the AIO.Org: Klinikum rechts der Isar, Technische Universität München, Klinik für Innere Medizin III, Munich, Germany, Munich, Germany, Krankenhaus Nordwest, University Cancer Center Frankfurt, Frankfurt Am Main, Germany, Universitätsklinikum Ulm, Klinik für Innere Medizin I, Ulm, Germany, Städtisches Klinikum Dresden, IV. Medical Clinic, Dresden, Germany, CaritasKlinikum Saarbrücken, Klinik für Hämatologie und Onkologie, Saarbrücken, Germany,
Abstract
Sexual health among cancer patients on active chemotherapy: A cross-sectional study from tertiary care cancer center in India.Org: IRCH, AIIMS New Delhi, Delhi, India, All India Institute of Medical Sciences (AIIMS), Rishikesh, India, New Delhi, India,
Abstract
The financial toxicity of chemotherapy in Belize.Org: University of Rochester School of Medicine & Dentistry, Stanford Hospital & Clinics, Saint Louis University School of Medicine, UCSF School of Medicine, Karl Heusner Memorial Hospital,
Abstract
Outcomes of pancreatic malignancy in octogenarians: A single tertiary center experience.Org: Moffitt Cancer Center and Research Institute, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Senior Adult Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Oncology Unit S. Chiara Hospital, Trento, Italy,
Abstract
The impact of Covid-19 pandemic on breast cancer multidisciplinary management at the Vall d'Hebron University Hospital.Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Oncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d´Hebron Institute of Oncology (VHIO),
Abstract
Real world utilization and outcomes of immunotherapy regimens in metastatic castration resistant prostate cancer (mCRPC).Org: Tisch Cancer Institute, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY,
Abstract
Analysis of the efficacy and safety of PD-1/PD-L1 inhibitors–based treatment in myxofibrosarcoma: A single-institution retrospective analysis.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Cardiovascular comorbidities and cardiovascular events in patients with metastatic prostate cancer.Org: Laboratoire Toxicomed, University of Tlemcen, Tidjani Damerdji Teaching Hospital, CHU Tlemcen,
Abstract
Pan-cancer analysis to identify molecules interacting with CasL-Like 2 to promote angiogenesis via mTOR/HIF1A/VEGFA pathway in hypoxia tumor environment.Org: The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, Nanjing, Jiangsu, China, the First Affiliated Hospital of Nanjing Medical University, Yancheng First People's Hospital, Yancheng, Jiangsu, China,
Abstract
Clinical factors associated with prescribing patterns of bone modifying agents in men with metastatic castration-resistant prostate cancer.Org: Michigan Medicine, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, Ann Arbor Veterans Health Administration, University of Wisconsin Madison School of Medicine and Public Health,
Abstract
Uterine sarcoma patients who underwent morcellation: Who are they? Results of the prospective intergroup real-world registry for gynecological sarcoma in Germany (REGSA- NOGGO RU1).Org: Charité - Universitätsmedizin Berlin, Berlin, Germany, Helios Klinikum Berlin-Buch, Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung/Knappschaft GmbH, Tuebingen University Hospital,
Abstract
Mini-hyper-CVD with venetoclax (Ven) for patients with relapsed/refractory (R/R) Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL): A phase II study.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Effect of upfront HSCT on patients with T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma at high risk of relapse: Single center retrospective observational study on minority rich population.Org: Jacobi Medical Center/Albert Einstein College of Medicine, Universal College of Medical Sciences, Montefiore Medical Center, Department of Medical Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY, Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine,
Abstract
Long term disease-free survival in locoregional, metastatic and/or recurrent UCNT.Org: EPH Ibn Zohr, Guelma, Algeria,
Abstract
Cost-effective analysis of rotational intraperitoneal aerosol chemotherapy (RIPAC) in patients with platinum-resistant ovarian cancer.Org: Seoul National University Hospital, Seoul National University College of Medicine,
Abstract
Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Results from a multi-cohort, multicenter phase II trial (ALTER-G-001).Org: Ruijin Hospital, Shanghai Jiaotong University School, Shanghai, China, Shanghai Jiao Tong University School of Medicine, Jiading Central Hospital, Affiliated Hospital of Jiangnan University (Wuxi Fourth People's Hospital), Wuxi Branch of Ruijin Hospital,
Abstract
Outcomes of stage IV non-small cell lung cancer patients after failure of platinum-based chemotherapy in clinical trials and real-world settings: A literature review.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, National University Cancer Institute Singapore, Real Chemistry, Inc., Novocure Inc., NovoCure,
Abstract
Evaluation of the prevalence of MET and protein tyrosine kinase 7 expression in non-small cell lung cancer to evaluate overlap of ADC antigens.Org: AbbVie Inc., North Chicago, IL, University of Colorado Denver Department of Radiation Oncology, University Hospital Birmingham NHS Foundation Trust, City of Hope Comprehensive Cancer Center, Shanghai Lung Cancer Center,
Drug
TTFieldsDrug
plinabulinDrug
VinorelbineDrug
Sabizabulin